Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avalglucosidase Alfa in Chinese Participants With Infantile-onset Pompe Disease (IOPD)
NCT06666413Phase 4Recruiting
- Sponsor
- Sanofi
- Start
- May 2025
- Primary completion
- May 2028
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of avalglucosidase alfa in Pompe disease, sponsored by Sanofi. Started May 2025; status: recruiting.
02
Drugs
avalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT06666413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666413.